Top

Archives of Gynecology and Obstetrics

Published in:

01-02-2018 | Gynecologic Endocrinology and Reproductive Medicine

Assessment of ovarian function after chemotherapy in women with early and locally advanced breast cancer from Serbia

Authors: Emina Malisic, Snezana Susnjar, Jelena Milovanovic, Natasa Todorovic-Rakovic, Vesna Kesic

Published in: Archives of Gynecology and Obstetrics | Issue 2/2018

Abstract

Purpose

Among harmful effects of chemotherapy is the reduction of ovarian function. The aim was to determine the serum levels of FSH, LH, estradiol and AMH after chemotherapy followed by endocrine therapy in breast cancer patients.

Methods

The study included 40 premenopausal hormone receptor-positive breast cancer patients aged 33–50 years. Anthracycline-based chemotherapy received 14/40 while anthracycline–taxane combination received 26/40 of patients, followed by tamoxifen (30/40) or tamoxifen plus goserelin (10/40). All of them experienced chemotherapy-induced secondary amenorrhea. Hormone levels were determined by ELISA. Statistics included Spearman’s test, Mann–Whitney test and multiple linear regression analysis.

Results

Undetectable AMH levels were observed in 62.5 and 33.3% of patients with time period < 2 and ≥ 2 years from completion of chemotherapy to sample collection. Median levels of hormones for patients treated with anthracycline-based compared to anthracycline–taxane therapy were: 15.5 vs. 22.3 IU/L for FSH; 10.9 vs. 13.6 IU/L for LH; 55.5 vs. 39.5 pg/mL for estradiol; 0.11 vs. 0.11 ng/mL for AMH. The multiple linear regression showed that: women who received goserelin had significantly lower FSH; those with shorter time from completion of chemotherapy to sample collection had significantly higher LH and lower estradiol; younger women had higher AMH levels.

Conclusions

The ovarian function was recovered from chemotherapy-induced secondary amenorrhea with time elapsed since the completion of adjuvant chemotherapy. It may be less disrupted in patients who received anthracycline-based chemotherapy and goserelin plus tamoxifen, as well.

Fleischer RT, Vollenhoven BJ, Weston GC (2011) The effects of chemotherapy and radiotherapy on fertility in premenopausal women. Obstet Gynecol Surv 66:248–254. https://doi.org/10.1097/OGX.0b013e318224e97b CrossRefPubMed

Johnston RJ, Wallace WHB (2009) Normal ovarian function and assessment of ovarian reserve in the survivor of childhood cancer. Pediatr Blood Cancer 53:296–302. https://doi.org/10.1002/pbc.22012 CrossRefPubMed

Henry NL, Xia R, Schott AF et al (2014) Prediction of postchemotherapy ovarian function using markers of ovarian reserve. Oncologist 19:68–74. https://doi.org/10.1634/theoncologist.2013-0145 CrossRefPubMed

Lappi M, Borini A (2012) Fertility preservation in women after the cancer. Curr Pharm Des 18:293–302CrossRefPubMed

Bozza C, Puglisi F, Lambertini M et al (2014) Anti-Mullerian hormone: determination of ovarian reserve in early breast cancer patients. Endocr Relat Cancer 21:R51–R65. https://doi.org/10.1530/ERC-13-0335 CrossRefPubMed

Zavos A, Valachis A (2016) Risk of chemotherapy-induced amenorrhea in patients with breast cancer: a systematic review and meta-analysis. Acta Oncol 55:664–670. https://doi.org/10.3109/0284186X.2016.1155738 CrossRefPubMed

Lass A (2001) Assessment of ovarian reserve—is there a role for ovarian biopsy? Hum Reprod 16:1055–1057CrossRefPubMed

Coccia ME, Rizzello F (2008) Ovarian reserve. Ann N Y Acad Sci 1127:27–30. https://doi.org/10.1196/annals.1434.011 CrossRefPubMed

Bernard DJ, Fortin J, Wang Y, Lamba P (2010) Mechanisms of FSH synthesis: what we know, what we don’t, and why you should care. Fertil Steril 93:2465–2485. https://doi.org/10.1016/j.fertnstert.2010.03.034 CrossRefPubMed

10.

Vegetti W, Alagna F (2006) FSH and folliculogenesis: from physiology to ovarian stimulation. Reprod Biomed Online 12:684–694CrossRefPubMed

11.

Huhtaniemi I (2015) A short evolutionary history of FSH-stimulated spermatogenesis. Hormones (Athens) 14:468–478. https://doi.org/10.14310/horm.2002.1632

12.

Christensen A, Bentley G, Cabrera R et al (2012) Hormonal regulation of female reproduction. Horm Metab Res 44:587–591. https://doi.org/10.1055/s-0032-1306301 CrossRefPubMedPubMedCentral

13.

Burger HG (2001) Physiological principles of endocrine replacement: estrogen. Horm Res 56(Suppl 1):82–85PubMed

14.

Suzuki S, Brown CM, Wise PM (2006) Mechanisms of neuroprotection by estrogen. Endocrine 29:209–216. https://doi.org/10.1385/ENDO:29:2:209 CrossRefPubMed

15.

Visser JA, Schipper I, Laven JSE, Themmen APN (2012) Anti-Müllerian hormone: an ovarian reserve marker in primary ovarian insufficiency. Nat Rev Endocrinol 8:331–341. https://doi.org/10.1038/nrendo.2011.224 CrossRefPubMed

16.

Robertson DM (2012) Inhibins and activins in blood: predictors of female reproductive health? Mol Cell Endocrinol 359:78–84. https://doi.org/10.1016/j.mce.2011.05.016 CrossRefPubMed

17.

Ben-Aharon I, Shalgi R (2012) What lies behind chemotherapy-induced ovarian toxicity? Reproduction 144:153–163. https://doi.org/10.1530/REP-12-0121 CrossRefPubMed

18.

Blumenfeld Z (2012) Chemotherapy and fertility. Best Pract Res Clin Obstet Gynaecol 26:379–390. https://doi.org/10.1016/j.bpobgyn.2011.11.008 CrossRefPubMed

19.

Meirow D, Biederman H, Anderson RA, Wallace WHB (2010) Toxicity of chemotherapy and radiation on female reproduction. Clin Obstet Gynecol 53:727–739. https://doi.org/10.1097/GRF.0b013e3181f96b54 CrossRefPubMed

20.

Broer SL, Broekmans FJM, Laven JSE, Fauser BCJM (2014) Anti-Mullerian hormone: ovarian reserve testing and its potential clinical implications. Hum Reprod Update 20:688–701. https://doi.org/10.1093/humupd/dmu020 CrossRefPubMed

21.

Peluso C, Fonseca FLA, Rodart IF et al (2014) AMH: an ovarian reserve biomarker in assisted reproduction. Clin Chim Acta 437:175–182. https://doi.org/10.1016/j.cca.2014.07.029 CrossRefPubMed

22.

Lutchman Singh K, Muttukrishna S, Stein RC et al (2007) Predictors of ovarian reserve in young women with breast cancer. Br J Cancer 96:1808–1816. https://doi.org/10.1038/sj.bjc.6603814 CrossRefPubMedPubMedCentral

23.

Anders C, Marcom PK, Peterson B et al (2008) A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer. Cancer Invest 26:286–295. https://doi.org/10.1080/07357900701829777 CrossRefPubMedPubMedCentral

24.

Reh A, Oktem O, Oktay K (2008) Impact of breast cancer chemotherapy on ovarian reserve: a prospective observational analysis by menstrual history and ovarian reserve markers. Fertil Steril 90:1635–1639. https://doi.org/10.1016/j.fertnstert.2007.09.048 CrossRefPubMed

25.

Yu B, Douglas N, Ferin MJ et al (2010) Changes in markers of ovarian reserve and endocrine function in young women with breast cancer undergoing adjuvant chemotherapy. Cancer 116:2099–2105. https://doi.org/10.1002/cncr.25037 PubMedPubMedCentral

26.

Su HI, Sammel MD, Green J et al (2010) Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors. Cancer 116:592–599. https://doi.org/10.1002/cncr.24746 CrossRefPubMedPubMedCentral

27.

Partridge AH, Ruddy KJ, Gelber S et al (2010) Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer. Fertil Steril 94:638–644. https://doi.org/10.1016/j.fertnstert.2009.03.045 CrossRefPubMed

28.

Anderson RA, Rosendahl M, Kelsey TW, Cameron DA (2013) Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer. Eur J Cancer 49:3404–3411. https://doi.org/10.1016/j.ejca.2013.07.014 CrossRefPubMedPubMedCentral

29.

Hamy A-S, Porcher R, Cuvier C et al (2014) Ovarian reserve in breast cancer: assessment with anti-Müllerian hormone. Reprod Biomed Online 29:573–580. https://doi.org/10.1016/j.rbmo.2014.07.008 CrossRefPubMed

30.

Tiong V, Rozita AM, Taib NA et al (2014) Incidence of chemotherapy-induced ovarian failure in premenopausal women undergoing chemotherapy for breast cancer. World J Surg 38:2288–2296. https://doi.org/10.1007/s00268-014-2542-y CrossRefPubMed

31.

Bala J, Seth S, Dhankhar R, Ghalaut VS (2016) Chemotherapy: impact on anti-Müllerian hormone levels in breast carcinoma. J Clin Diagn Res 10:BC19–BC21. https://doi.org/10.7860/JCDR/2016/15933.7328 PubMedPubMedCentral

32.

Liem GS, Mo FKF, Pang E et al (2015) Chemotherapy-related amenorrhea and menopause in young chinese breast cancer patients: analysis on incidence, risk factors and serum hormone profiles. PLoS One 10:e0140842. https://doi.org/10.1371/journal.pone.0140842 CrossRefPubMedPubMedCentral

33.

Ben-Aharon I, Granot T, Meizner I et al (2015) Long-term follow-up of chemotherapy-induced ovarian failure in young breast cancer patients: the role of vascular toxicity. Oncologist 20:985–991. https://doi.org/10.1634/theoncologist.2015-0044 CrossRefPubMedPubMedCentral

34.

Long J-P, Wan F, Zhang F et al (2016) DTC chemotherapy regimen is associated with higher incidence of premature ovarian failure in women of reproductive age with breast cancer. Eur Rev Med Pharmacol Sci 20:1087–1092PubMed

35.

Berliere M, Duhoux FP, Dalenc F et al (2013) Tamoxifen and ovarian function. PLoS One 8:e66616. https://doi.org/10.1371/journal.pone.0066616 CrossRefPubMedPubMedCentral

36.

Montemurro F, Del Mastro L, De Laurentiis M, Puglisi F (2016) Endocrine therapy in premenopausal women with breast cancer: a critical appraisal of current evidence. Expert Rev Anticancer Ther 16:211–218. https://doi.org/10.1586/14737140.2016.1128327 CrossRefPubMed

37.

Senkus E, Kyriakides S, Ohno S et al (2015) Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 26:v8–v30. https://doi.org/10.1093/annonc/mdv298 CrossRefPubMed

38.

Klijn JG, Blamey RW, Boccardo F et al (2001) Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 19:343–353. https://doi.org/10.1200/JCO.2001.19.2.343 CrossRefPubMed

39.

Barbakadze L, Kristesashvili J, Khonelidze N, Tsagareishvili G (2015) The correlations of anti-mullerian hormone, follicle-stimulating hormone and antral follicle count in different age groups of infertile women. Int J Fertil Steril 8:393–398PubMedPubMedCentral

40.

Lee JE, Yoon SH, Kim HO, Min EG (2015) Correlation between the serum luteinizing hormone to folliclestimulating hormone ratio and the anti-Müllerian hormone levels in normo-ovulatory women. J Korean Med Sci 30:296. https://doi.org/10.3346/jkms.2015.30.3.296 CrossRefPubMedPubMedCentral

41.

Rama Raju G, Chavan R, Deenadayal M et al (2013) Luteinizing hormone and follicle stimulating hormone synergy: a review of role in controlled ovarian hyper-stimulation. J Hum Reprod Sci 6:227. https://doi.org/10.4103/0974-1208.126285 CrossRef

42.

Lambalk CB, van Disseldorp J, de Koning CH, Broekmans FJ (2009) Testing ovarian reserve to predict age at menopause. Maturitas 63:280–291. https://doi.org/10.1016/j.maturitas.2009.06.007 CrossRefPubMed

43.

Rosendahl M, Andersen CY, la Cour Freiesleben N et al (2010) Dynamics and mechanisms of chemotherapy-induced ovarian follicular depletion in women of fertile age. Fertil Steril 94:156–166. https://doi.org/10.1016/j.fertnstert.2009.02.043 CrossRefPubMed

44.

Anderson RA, Themmen APN, Qahtani AA et al (2006) The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum Reprod 21:2583–2592. https://doi.org/10.1093/humrep/del201 CrossRefPubMed

45.

Zhao J, Liu J, Chen K et al (2014) What lies behind chemotherapy-induced amenorrhea for breast cancer patients: a meta-analysis. Breast Cancer Res Treat 145:113–128. https://doi.org/10.1007/s10549-014-2914-x CrossRefPubMed

46.

Badawy A, Elnashar A, El-Ashry M, Shahat M (2009) Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril 91:694–697. https://doi.org/10.1016/j.fertnstert.2007.12.044 CrossRefPubMed

47.

Clowse MEB, Behera MA, Anders CK et al (2009) Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis. J Women’s Heal 18:311–319. https://doi.org/10.1089/jwh.2008.0857 CrossRef

48.

Del Mastro L, Catzeddu T, Boni L et al (2006) Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients. Ann Oncol 17:74–78. https://doi.org/10.1093/annonc/mdj029 CrossRefPubMed

49.

Lambertini M, Ceppi M, Poggio F et al (2015) Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies. Ann Oncol 26:mdv374. https://doi.org/10.1093/annonc/mdv374 CrossRef

50.

Moore HCF, Unger JM, Phillips K-A et al (2015) Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med 372:923–932. https://doi.org/10.1056/NEJMoa1413204 CrossRefPubMedPubMedCentral

51.

Shen YW, Zhang XM, Lv M et al (2015) Utility of gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage in premenopausal women with breast cancer: a systematic review and meta-analysis. Onco Targets Ther 8:3349. https://doi.org/10.2147/OTT.S95936 CrossRefPubMedPubMedCentral

52.

Sverrisdottir A, Nystedt M, Johansson H, Fornander T (2009) Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. Breast Cancer Res Treat 117:561–567. https://doi.org/10.1007/s10549-009-0313-5 CrossRefPubMed

53.

Magon N (2011) Gonadotropin releasing hormone agonists: expanding vistas. Indian J Endocrinol Metab 15:261. https://doi.org/10.4103/2230-8210.85575 CrossRefPubMedPubMedCentral

Title: Assessment of ovarian function after chemotherapy in women with early and locally advanced breast cancer from Serbia
Authors: Emina Malisic
Snezana Susnjar
Jelena Milovanovic
Natasa Todorovic-Rakovic
Vesna Kesic
Publication date: 01-02-2018
Publisher: Springer Berlin Heidelberg
Published in: Archives of Gynecology and Obstetrics / Issue 2/2018
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-017-4581-8

At a glance: The STEP trials

Springer Medicine

Assessment of ovarian function after chemotherapy in women with early and locally advanced breast cancer from Serbia

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2018

RASSF1A promoter methylation was associated with the development, progression and metastasis of cervical carcinoma: a meta-analysis with trial sequential analysis

Stimulation of chemokines in human endometrial stromal cells by tumor necrosis factor-α and interferon-γ is similar under apoptotic and non-apoptotic conditions

Hyperandrogenemia and ovarian reserve in patients with Mayer–Rokitansky–Küster–Hauser syndrome type 1 and 2: potential influences on ovarian stimulation

Clinical effect of emergency cervical cerclage and elective cervical cerclage on pregnancy outcome in the cervical-incompetent pregnant women

Response to the Letter to the Editor by Dr. Junaid Rafi

Laparoscopic-assisted vaginal hysterectomy versus vaginal hysterectomy for benign uterine diseases: a prospective, randomized, multicenter, double-blind trial (LAVA)